
    
      Parts 1 and 2 will each consist of 4 panels. In the first panel, a 200 mg dose of MK-7680
      will be administered. In each of the following 3 panels, higher or lower doses of MK-7680
      will be administered. Each panel will only begin once the safety and tolerability data from
      the preceding panel have been evaluated.
    
  